Ensign Peak Advisors
RAPT

Ensign Peak Advisors’s RAPT Therapeutics RAPT Stock Holding History

Ensign Peak Advisors’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-843
Closed -$162K – 2123
2022
Q3 		$162K Buy
843
+242
+40% +$45.8K ﹤0.01% 1946
2022
Q2 		$88K Hold
601
– – ﹤0.01% 1985
2022
Q1 		$106K Sell
601
-1,532
-72% -$289K ﹤0.01% 2021
2021
Q4 		$627K Buy
2,133
+602
+39% +$161K ﹤0.01% 1526
2021
Q3 		$380K Buy
+1,531
New +$405K ﹤0.01% 1676

Other funds holding RAPT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Ensign Peak Advisors's RAPT Position: Q4 2022 in Review

Ensign Peak Advisors sold out of RAPT Therapeutics (RAPT) in Q4 2022, closing a stake of 843 shares — an estimated $162K sold.

Ensign Peak Advisors first reported a position in RAPT in Q3 2021 and held it in 5 quarters. The position peaked at $627K in Q4 2021. 95 funds tracked by Wall St. Rank hold RAPT as of Q4 2022.

  • Ensign Peak Advisors reported no remaining RAPT Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 843 RAPT Therapeutics shares in Q4 2022, an estimated $162K.
  • Ensign Peak Advisors first reported a position in RAPT Therapeutics in Q3 2021 and held it in 5 quarters.
  • Ensign Peak Advisors's RAPT Therapeutics position peaked at $627K in Q4 2021.
  • 95 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.